DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Zandberg DP, Algazi AP, Jimeno A. et al.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Eur J Cancer 2019;
107 (107) 142-152
We do not assume any responsibility for the contents of the web pages of other providers.